Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
NA-831 + atazanavir
- Development stage
- Unknown
- Lead developer
- Biomed
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
**NA-831 + atazanavir** is an investigational combination therapy consisting of NA-831 (also known as Traneurocin), a neuroprotective and neurogenic small molecule originally developed for Alzheimer's disease, together with atazanavir, an approved antiretroviral protease inhibitor. The combination is being studied for use in treating COVID-19, with NA-831 aimed at reducing neurological and cognitive deficits (by promoting neurogenesis and neuroprotection), and atazanavir targeting SARS-CoV-2 viral replication. This combination is part of a broader Phase 2/3 clinical study investigating its efficacy and safety, especially in hospitalized COVID-19 patients, with the goal to improve clinical recovery and reduce neurological sequelae.
- Brand names
- Traneurocin
02
Targets
AMPAR (AMPA receptor)Mpro (3C-like proteinase of SARS-CoV-2)PR (Progesterone receptor)
Beyond the preview
Go deeper on NA-831 + atazanavir.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NA-831 + atazanavir.